S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
NASDAQ:GNPX

Genprex (GNPX) Stock Price, News & Analysis

$2.31
-0.04 (-1.70%)
(As of 04/16/2024 ET)
Today's Range
$2.27
$2.43
50-Day Range
$2.40
$6.00
52-Week Range
$2.27
$46.00
Volume
20,368 shs
Average Volume
76,211 shs
Market Capitalization
$4.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Genprex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
332.9% Upside
$10.00 Price Target
Short Interest
Healthy
3.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.77) to ($2.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

GNPX stock logo

About Genprex Stock (NASDAQ:GNPX)

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

GNPX Stock Price History

GNPX Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Genprex To Expand Non-clinical Program To Study TUSC2, NPRL2
See More Headlines
Receive GNPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/01/2019
Today
4/16/2024
Next Earnings (Estimated)
5/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GNPX
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+334.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-30,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.99 per share

Miscellaneous

Free Float
1,690,000
Market Cap
$4.39 million
Optionable
Optionable
Beta
-0.61
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. John Rodney Varner (Age 67)
    Co-Founder, Chairman, President & CEO
    Comp: $886.97k
  • Mr. Ryan M. Confer M.S. (Age 42)
    Chief Financial Officer
    Comp: $606.57k
  • Mr. David M. Schloss
    Senior Vice President of Human Resources
  • Mr. Thomas C. Gallagher Esq.
    Senior Vice President of Intellectual Property & Licensing
  • Dr. Mark S. Berger M.D. (Age 69)
    Chief Medical Officer
  • Dr. Suzanne Thornton-Jones
    Senior Vice President of Regulatory Affairs & Quality
  • Dr. Jack A. Roth F.A.C.S.
    M.D., Chairman of Scientific & Medical Advisory Board

GNPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Genprex stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GNPX shares.
View GNPX analyst ratings
or view top-rated stocks.

What is Genprex's stock price target for 2024?

1 Wall Street research analysts have issued 1 year target prices for Genprex's shares. Their GNPX share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 332.9% from the stock's current price.
View analysts price targets for GNPX
or view top-rated stocks among Wall Street analysts.

How have GNPX shares performed in 2024?

Genprex's stock was trading at $9.20 at the start of the year. Since then, GNPX shares have decreased by 74.9% and is now trading at $2.31.
View the best growth stocks for 2024 here
.

Are investors shorting Genprex?

Genprex saw a drop in short interest in March. As of March 31st, there was short interest totaling 70,000 shares, a drop of 12.8% from the March 15th total of 80,300 shares. Based on an average daily volume of 83,200 shares, the short-interest ratio is currently 0.8 days. Currently, 3.8% of the company's shares are short sold.
View Genprex's Short Interest
.

When is Genprex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our GNPX earnings forecast
.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) posted its quarterly earnings data on Monday, April, 1st. The company reported ($9.20) earnings per share for the quarter, missing the consensus estimate of ($5.40) by $3.80.

When did Genprex's stock split?

Shares of Genprex reverse split on the morning of Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNPX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners